<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mosely, Mary</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Nilsson, Peter M.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">CV Protection by Antihyperglycemic Drugs: Evidence from Clinical Trials</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">14-15</style></pages><abstract><style  face="normal" font="default" size="100%">This article discusses the evidence from clinical trials addressing the reduction of cardiovascular (CV) risk with antihyperglycemic drugs. Specific trials include the UKPDS, ACCORD, RECORD, NAVIGATOR, and ORIGIN trials, as well as a number of ongoing clinical trials examining the CV safety of dipeptidyl peptidase-4 inhibitors.</style></abstract><number><style face="normal" font="default" size="100%">9</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>